maraviroc- maraviroc tablet, film coated
camber pharmaceuticals, inc. - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. limitations of use: • maraviroc tablets are not recommended in patients with dual/mixed- or cxcr4-tropic hiv-1 [ see microbiology ( 12.4) ]. maraviroc tablets are contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [ see warnings and precautions ( 5.3) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to maraviroc during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of maraviroc during pregnancy from the apr and case reports are not suffi
maraviroc- maraviroc tablet, film coated
xlcare pharmaceuticals inc. - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. limitations of use: • maraviroc tablets are not recommended in patients with dual/mixed- or cxcr4-tropic hiv-1 [see microbiology ( 12.4)]. maraviroc tablets are contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions ( 5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to maraviroc during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of maraviroc during pregnancy from the apr and
selzentry- maraviroc tablet, film coated selzentry- maraviroc solution selzentry- maraviroc kit
viiv healthcare company - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 25 mg - selzentry is indicated in combination with other antiretroviral agents for the treatment of only ccr5‑tropic human immunodeficiency virus type 1 (hiv‑1) infection in adult and pediatric patients weighing at least 2 kg. limitations of use selzentry is contraindicated in patients with severe renal impairment or esrd (creatinine clearance [crcl] less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to selzentry during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of selzentry during pregnancy from the apr and case reports are not sufficient to inform a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, no evidence of adverse developmental outcomes was observed with
selzentry- maraviroc tablet, film coated
a-s medication solutions - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 300 mg - selzentry is indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in patients 2 years of age and older weighing at least 10 kg. limitations of use: selzentry is contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to selzentry during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of selzentry during pregnancy from the apr and case reports are not sufficient to inform a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, no evidence of adverse developmental outcomes was observed with maraviroc. durin
maraviroc tablet, film coated
i3 pharmaceuticals, llc - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc is indicated in combination with other antiretroviral agents for the treatment of only ccr5‑tropic human immunodeficiency virus type 1 (hiv‑1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. limitations of use - maraviroc is not recommended in patients with dual/mixed- or cxcr4-tropic hiv- 1 [see microbiology (12.4)] . maraviroc is contraindicated in patients with severe renal impairment or esrd (creatinine clearance [crcl] less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to maraviroc during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of maraviroc during pregnancy from the apr and case reports are not sufficient to
selzentry maraviroc tablet film coated
pfizer laboratories div pfizer inc - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 150 mg
selzentry- maraviroc tablet, film coated
physicians total care, inc. - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 300 mg - selzentry, in combination with other antiretroviral agents, is indicated for adult patients infected with only ccr5-tropic hiv-1. this indication is based on analyses of plasma hiv-1 rna levels in two controlled studies of selzentry in treatment-experienced subjects and one study in treatment-naïve subjects. both studies in treatment-experienced subjects were conducted in clinically advanced, 3-class antiretroviral-experienced (nrti, nnrti, pi, or enfuvirtide) adults with evidence of hiv-1 replication despite ongoing antiretroviral therapy. the following points should be considered when initiating therapy with selzentry: - adult patients infected with only ccr5-tropic hiv-1 should use selzentry. - tropism testing must be conducted with a highly sensitive tropism assay that has demonstrated the ability to identify patients appropriate for selzentry use. outgrowth of pre-existing low-level cxcr4- or dual/mixed-tropic hiv-1 not detected by tropism testing at screening has been associated with virologic failure o
celsentri maraviroc 300 mg tablets blister packs
viiv healthcare pty ltd - maraviroc, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; calcium hydrogen phosphate; colour - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1.,the use of other active agents with celsentri is associated with a greater likelihood of treatment response.
celsentri maraviroc 150 mg tablets blister packs
viiv healthcare pty ltd - maraviroc, quantity: 150 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; colour - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1. the use of other active agents with celsentri is associated with a greater likelihood of treatment response.
selzentry- maraviroc tablet, film coated
a-s medication solutions - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - selzentry is indicated in combination with other antiretroviral agents for the treatment of only ccr5‑tropic human immunodeficiency virus type 1 (hiv‑1) infection in adult and pediatric patients weighing at least 2 kg. limitations of use selzentry is contraindicated in patients with severe renal impairment or esrd (creatinine clearance [crcl] less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to selzentry during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of selzentry during pregnancy from the apr and case reports are not sufficient to inform a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, no evidence of adverse developmental outcomes was observed with